Goltz, D
Gevensleben, H
Grünen, S
Dietrich, J
Kristiansen, G
Landsberg, J
Dietrich, D
Article History
First Online: 14 November 2016
Competing interests
: DD has been an employee and is a stockholder of Epigenomics AG. DD is inventor and co-inventor and owns patents on methylation biomarkers and related technologies. DD receives inventor’s compensation from Epigenomics AG. DD is a consultant for AJ Innuscreen GmbH (Berlin, Germany) and receives royalties from product sales. DD is a consultant and receives or received compensation from Therawis GmbH (Munich, Germany), Oncgnostics GmbH (Jena, Germany), MDxHealth, Inc. (Irvine, CA, USA), Epigenomics AG (Berlin, Germany) and R-Biopharm AG (Darmstadt, Germany). A patent on methylation of immune checkpoint genes (incl. <i>CD274</i>, <i>PDCD1</i>, <i>PDCD1LG2</i>, and <i>CTLA4</i>) as predictive and prognostic biomarkers is pending (inventor: Dimo Dietrich). The remaining authors declare no conflict of interest.